Enveric Biosciences Inc(ENVB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 30 at 4:10 PM ET (Korea 10/1 05:10)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -16.46 | Insider Own | 1.64% | Shs Outstand | 4.5M | Perf Week | -4.79% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 4.4M | Perf Month | 8.76% |
| Enterprise Value | -0.00B | PEG | - | EPS next Q | - | Inst Own | 11.84% | Short Float | 0.52% | Perf Quarter | -0.67% |
| Income | -0.01B | P/S | - | EPS this Y | - | Inst Trans | 14.33% | Short Ratio | 0.22 | Perf Half Y | -23.2% |
| Sales | 0.00B | P/B | 0.73 | EPS next 5Y | - | ROA | -139.75% | Short Interest | 0.02M | Perf YTD | -58.95% |
| Book/sh | 2.05 | P/C | 0.8 | EPS past 3/5Y | 75.07% 67.96% | ROE | -170.04% | 52W High | -88.75% ($13.25) | Perf Year | -80.58% |
| Cash/sh | 1.85 | P/FCF | - | Sales past 3/5Y | - | ROIC | -108% | 52W Low | 27.34% ($1.17) | Perf 3Y | -99.65% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 87.05% | Gross Margin | - | Volatility(W/M) | 5.42% 5.85% | Perf 5Y | -99.99% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.1 | Perf 10Y | -100% |
| Dividend Ex-Date | - | Quick Ratio | 10.21 | EPS Q/Q | 93.48% | Profit Margin | - | RSI (14) | 50.53 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 10.21 | Sales Q/Q | - | SMA20 | 0.05% ($1.49) | Beta | 1.19 | Target Price | $1800 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/14 | SMA50 | 1.82% ($1.46) | Rel Volume | 0.52 | Prev Close | $1.45 |
| Employees | 6 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | -36.52% ($2.35) | Avg Volume(3M) | 0.11M | Price | $1.49 |
| IPO | 1995/8/22 | Option/Short | No/Yes | Trades | 270 | Volume | 54,671 | Change | 2.76% |
🧠 is a US clinical-stage micro-cap biotech developing novel neuropsychiatric drugs. Its lead candidate, EB-003, is a non-hallucinogenic psychedelic-like compound designed to induce neuroplasticity while minimizing hallucinogenic effects, targeting outpatient treatment for depression, PTSD, and anxiety disorders. The company also holds additional pipeline assets, including the EVM301 series.
Over the past 1 year, on the lower side
89% below its 1-year high.
Traded less than usual That is 52% of its average volume.
ENVB has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 3 quarters.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +78% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 11.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
PSIL AdvisorShares Psychedelics ETF <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% It ranks #537 of 592 in the industry
Based on market cap of $7M.
AIM#536 AIM ImmunoTech Inc $7M PER - ENVB#537 Enveric Biosciences Inc $7M PER - 
CANF#537 Can-Fite Biopharma Ltd ADR $7M PER - 
LNAI#539 Lunai Bioworks Inc $7M PER - 
LEXX#540 Lexaria Bioscience Corp $7M PER - 
FAQ
What kind of company is ENVB?
ENVB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ENVB?
The market cap of ENVB is approximately $7M, ranking 5,615 within its sector.
What is the 52-week high and low for ENVB?
ENVB has recorded a 52-week high of $13.25 and a low of $1.17.
